A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms MAGNIFY
- Sponsors Celgene Corporation
- 01 Oct 2024 Status changed from active, no longer recruiting to completed.
- 26 Aug 2024 Planned End Date changed from 1 Aug 2024 to 23 Aug 2024.
- 26 Aug 2024 Planned primary completion date changed from 1 Aug 2024 to 23 Aug 2024.